European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Drug Development 98

Drug Development Drug Pricing Communication 98

Pharmaceutical Technology

JUNE 29, 2022

Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drug pricing and limited patient access.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 98

STAT

MARCH 5, 2025

in 2001 to 27.2% Chronic diseases, such as diabetes, cancer, and cardiovascular disease, pose one of the most significant health threats to Americans today. The share of Americans with multiple chronic conditions increased from 21.8% In 2022, these illnesses claimed the lives of 1.9 Read the rest…

Drug Development 306

Drug Development Diabetes Drug Pricing 306